Who are BOL-303259-X's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Izervay, AVACINCAPTAD PEGOL SODIUM, Veopoz, Ultomiris, Ro 205720, Ultomiris.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/bol-303259-x.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

BOL-303259-X — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

BOL-303259-X (BOL-303259-X) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Complement C5 inhibitor. Area: Ophthalmology.

phase 3 Complement C5 inhibitor Complement C5 Ophthalmology Small molecule Live · refreshed every 30 min

Target snapshot

BOL-303259-X (BOL-303259-X) — Bausch & Lomb Incorporated. BOL-303259-X is a small molecule that inhibits the complement C5 pathway to reduce inflammation and tissue damage in the eye.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
BOL-303259-X TARGET	BOL-303259-X	Bausch & Lomb Incorporated	phase 3	Complement C5 inhibitor	Complement C5
Izervay	AVACINCAPTAD PEGOL	Astellas Pharma	marketed		Complement C5	2023-01-01
AVACINCAPTAD PEGOL SODIUM	AVACINCAPTAD PEGOL SODIUM		marketed	Complement Inhibitors	Complement C5	2023-01-01
Veopoz	POZELIMAB	Regeneron	marketed	Complement Inhibitor [EPC]	Complement C5	2023-01-01
Ultomiris	RAVULIZUMAB	AstraZeneca	marketed	Complement Inhibitor [EPC]	Complement C5	2018-01-01
Ro 205720	CARPROFEN	Roche	marketed	carprofen	Complement C5, Prostaglandin G/H synthase 1, Prostaglandin G/H synthase 2	1987-01-01
Ultomiris	Ultomiris	Alexion Pharmaceuticals, Inc.	marketed		Complement C5

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

2026-11-11 — AVACINCAPTAD PEGOL SODIUM · 8236773 · Method of Use · US
2027-02-14 — AVACINCAPTAD PEGOL SODIUM · 9617546 · Compound · US
2027-02-14 — AVACINCAPTAD PEGOL SODIUM · 7579456 · Compound · US
2034-07-11 — AVACINCAPTAD PEGOL SODIUM · 11491176 · Method of Use · US
2034-07-11 — AVACINCAPTAD PEGOL SODIUM · 11273171 · Method of Use · US
2034-07-11 — AVACINCAPTAD PEGOL SODIUM · 12016875 · Method of Use · US

Sponsor landscape (Complement C5 inhibitor class)

Alexion Pharmaceuticals, Inc. · 1 drug in this class
Bausch & Lomb Incorporated · 1 drug in this class
Massachusetts General Hospital · 1 drug in this class
University Hospital, Tours · 1 drug in this class
Wuhan Createrna Science and Technology Co., Ltd · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). BOL-303259-X — Competitive Intelligence Brief. https://druglandscape.com/ci/bol-303259-x. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab